Michel Dutree - Selling Sickness 2010
•
0 likes•422 views
This document discusses the importance of dialogue between pharmaceutical companies and society when making decisions about healthcare. It argues against an "us vs. them" approach and in favor of cooperation. The document notes some challenges around new drug approvals and reimbursement, and emphasizes that pharmaceutical companies should work with society to provide information and drive innovation, not make decisions for society alone. The overall message is that cooperation, not opposition, can lead to positive change.
Report
Share
Report
Share
![Entanglement with society ,[object Object]](data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7)
Recommended
Maritz channel partners
Channel rep incentive programs are effective according to a survey, with 77% of reps saying the programs highly influence their performance and 75% expending 80% more effort to achieve goals. However, many reps face multiple incentive programs from different sources. To be most effective, incentives should focus on individual performance and offer a combination of cash and non-cash rewards according to 70% and 94% of reps respectively.
10 Costly Sales Compensation Pitfalls - Pepperi
Slideshow from the popular webinar in which Pepperi hosted David Fritz – guru, thought leader, and frequent speaker in the field of sales rep compensation and incentive design. In the webinar David shared his incentive compensation pitfalls to avoid.
The slideshow features the main points for the roadmap for creating a highly motivating, simple, and coherent sales incentive program.
You will learn the do’s and don’ts of smart incentive programs, including:
- Challenges and pitfalls
- Design decisions
- Techniques to retain top talent
- Communication and change management
Best Practices for Sales Compensation Management
1. The document discusses best practices for sales compensation management and summarizes presentations from Christopher W. Cabrera of Xactly Corporation and Jeff Williams of IronPort Systems.
2. It describes the benefits of automated sales compensation management systems for both sales and finance teams, including compliance, reduced errors, and improved reporting.
3. It provides an example of how IronPort Systems leveraged Salesforce and Xactly to improve their sales compensation processes and increase sales productivity by reducing time spent on manual tasks.
Dean Baker Selling Sickness 2010
The document summarizes problems with the current pharmaceutical patent system and incentives it creates, and proposes publicly funding research and medical education instead. Key issues with patents include inefficient drug use and costs, focus on profitable treatments over needs, and distortions in research, education, and marketing. The proposal involves long-term master contracts totaling $30-40 billion annually for public research, requiring all results be openly shared online, and educating doctors with no drug company influence to improve priorities and transparency.
2017 First Quarter Professional Development Courses: Sales Incentive Compensa...
Practical, Actionable, No-Nonsense, High-Performance, High Impact Courses:
A1 Sales Incentive Compensation Design For Higher Performance And Impact: Practical Essentials For The Competitive Edge
A2 Sales Quotas Strategies For Achieving High(er) Performance: Diagnosis, Design, Development, Delivery & Decisions
B1 Compensation & Total Rewards Management Fundamentals For High Impact: Comprehensive Introduction To Leading-Edge, World-Class Practices & Principles, With Relevant Local Applications & Cases
B2 Designing 'Salary Structures' For Competitive, Strategy-Aligned Pay: From Salary Surveys To Modern ‘Market Pricing’ Methodologies, Etc.-- Deploying SMARTer Practices, Techniques, & Tools For High Impact
B3 Employee Engagement Strategies & Techniques For Sustainable High Performance: Deploying Proven Practices & Processes That Work In High-Performance Organizations
B4 Salary Survey Secrets For Competitive Pay & Performance: Planning, Prep., Providers, Participation, Parsing Data, Proposals To Management, & Processes In Between
Board, Chief Officer, Leadership, & Strategic Level Series
• Executive Compensation & Corporate Governance Fundamentals: Emerging Tools For Strategic Alignment, Risk Management, Competitive Pay, etc.
• Rewards Strategy For High Performance & The Competitive Edge: Developing & Leveraging What Works In Top-Performing Companies
• Designing Incentive And Bonus Programs For Improved Performance: Learning & Leveraging Practices & Principles Of Top-Performing Companies
• Radical New Developments In Performance Management: Why Major Companies Are Dumping Established Practices, And What You Need to Do Now
• Expatriate Compensation and Global Mobility Fundamentals: High Impact Practices & Principles For Our Increasingly Complex & Changing Global Village
Show me the money! Sales compensation plans that won't fail
Compensation plans are extremely powerful tools for influencing Sales results...when done right!
If done incorrectly, they can back-fire, demotivate and even distract to your sales team.
In this webinar, we will address the frequently asked question, "How do I design a compensation package for my sales team?"
Sales strategy consultant Michael Hanna will discuss the 7 critical, but commonly overlooked factors for designing and implementing sales compensation plans to keep your team focused and motivated.
Sales Compensation: Tips and Tricks to Building a Powerful Plan
This document discusses creating compensation plans, specifically for millennial sales hires. It provides examples of metrics and goals that could be used in a comp plan, such as number of appointments set and opportunities created. An effective comp plan is simple, has clear structure and goals. It also discusses how to calculate potential revenue per rep based on deal size and close rate for different customer segments. The document emphasizes that top performance results from achieving goals in multiple areas, not just one metric, and notes the importance of tracking activities in CRM.
Day of a Medical Representative
This document outlines the daily plan and best practices for a territory manager (TM). It includes:
1. Checking details from the last area visit, addressing any pending issues, and planning for the day with the planner and doctor conversion targets.
2. Arriving early to field to visit key chemists, conduct retail counter promotion activities (RCPA), and identify new customers.
3. Proper pre-call planning including sample organization and keeping visual aids protected.
4. Best practices for doctor visits including proper etiquette, effective detailing, addressing objections, and closing with commitments.
Recommended
Maritz channel partners
Channel rep incentive programs are effective according to a survey, with 77% of reps saying the programs highly influence their performance and 75% expending 80% more effort to achieve goals. However, many reps face multiple incentive programs from different sources. To be most effective, incentives should focus on individual performance and offer a combination of cash and non-cash rewards according to 70% and 94% of reps respectively.
10 Costly Sales Compensation Pitfalls - Pepperi
Slideshow from the popular webinar in which Pepperi hosted David Fritz – guru, thought leader, and frequent speaker in the field of sales rep compensation and incentive design. In the webinar David shared his incentive compensation pitfalls to avoid.
The slideshow features the main points for the roadmap for creating a highly motivating, simple, and coherent sales incentive program.
You will learn the do’s and don’ts of smart incentive programs, including:
- Challenges and pitfalls
- Design decisions
- Techniques to retain top talent
- Communication and change management
Best Practices for Sales Compensation Management
1. The document discusses best practices for sales compensation management and summarizes presentations from Christopher W. Cabrera of Xactly Corporation and Jeff Williams of IronPort Systems.
2. It describes the benefits of automated sales compensation management systems for both sales and finance teams, including compliance, reduced errors, and improved reporting.
3. It provides an example of how IronPort Systems leveraged Salesforce and Xactly to improve their sales compensation processes and increase sales productivity by reducing time spent on manual tasks.
Dean Baker Selling Sickness 2010
The document summarizes problems with the current pharmaceutical patent system and incentives it creates, and proposes publicly funding research and medical education instead. Key issues with patents include inefficient drug use and costs, focus on profitable treatments over needs, and distortions in research, education, and marketing. The proposal involves long-term master contracts totaling $30-40 billion annually for public research, requiring all results be openly shared online, and educating doctors with no drug company influence to improve priorities and transparency.
2017 First Quarter Professional Development Courses: Sales Incentive Compensa...
Practical, Actionable, No-Nonsense, High-Performance, High Impact Courses:
A1 Sales Incentive Compensation Design For Higher Performance And Impact: Practical Essentials For The Competitive Edge
A2 Sales Quotas Strategies For Achieving High(er) Performance: Diagnosis, Design, Development, Delivery & Decisions
B1 Compensation & Total Rewards Management Fundamentals For High Impact: Comprehensive Introduction To Leading-Edge, World-Class Practices & Principles, With Relevant Local Applications & Cases
B2 Designing 'Salary Structures' For Competitive, Strategy-Aligned Pay: From Salary Surveys To Modern ‘Market Pricing’ Methodologies, Etc.-- Deploying SMARTer Practices, Techniques, & Tools For High Impact
B3 Employee Engagement Strategies & Techniques For Sustainable High Performance: Deploying Proven Practices & Processes That Work In High-Performance Organizations
B4 Salary Survey Secrets For Competitive Pay & Performance: Planning, Prep., Providers, Participation, Parsing Data, Proposals To Management, & Processes In Between
Board, Chief Officer, Leadership, & Strategic Level Series
• Executive Compensation & Corporate Governance Fundamentals: Emerging Tools For Strategic Alignment, Risk Management, Competitive Pay, etc.
• Rewards Strategy For High Performance & The Competitive Edge: Developing & Leveraging What Works In Top-Performing Companies
• Designing Incentive And Bonus Programs For Improved Performance: Learning & Leveraging Practices & Principles Of Top-Performing Companies
• Radical New Developments In Performance Management: Why Major Companies Are Dumping Established Practices, And What You Need to Do Now
• Expatriate Compensation and Global Mobility Fundamentals: High Impact Practices & Principles For Our Increasingly Complex & Changing Global Village
Show me the money! Sales compensation plans that won't fail
Compensation plans are extremely powerful tools for influencing Sales results...when done right!
If done incorrectly, they can back-fire, demotivate and even distract to your sales team.
In this webinar, we will address the frequently asked question, "How do I design a compensation package for my sales team?"
Sales strategy consultant Michael Hanna will discuss the 7 critical, but commonly overlooked factors for designing and implementing sales compensation plans to keep your team focused and motivated.
Sales Compensation: Tips and Tricks to Building a Powerful Plan
This document discusses creating compensation plans, specifically for millennial sales hires. It provides examples of metrics and goals that could be used in a comp plan, such as number of appointments set and opportunities created. An effective comp plan is simple, has clear structure and goals. It also discusses how to calculate potential revenue per rep based on deal size and close rate for different customer segments. The document emphasizes that top performance results from achieving goals in multiple areas, not just one metric, and notes the importance of tracking activities in CRM.
Day of a Medical Representative
This document outlines the daily plan and best practices for a territory manager (TM). It includes:
1. Checking details from the last area visit, addressing any pending issues, and planning for the day with the planner and doctor conversion targets.
2. Arriving early to field to visit key chemists, conduct retail counter promotion activities (RCPA), and identify new customers.
3. Proper pre-call planning including sample organization and keeping visual aids protected.
4. Best practices for doctor visits including proper etiquette, effective detailing, addressing objections, and closing with commitments.
Sales promotion: basic sales promotion techniques
This document provides an overview of basic sales promotion techniques. It defines sales promotion as a planned marketing activity that enhances a product or service's appeal and positively changes consumer behavior in return for an additional benefit. The document outlines various types of sales promotions like temporary price discounts, coupons, bonus packs, sampling, premiums, and sweepstakes. It also discusses the impact of promotions on consumers in economic, emotional and informational ways. Additionally, the benefits of promotions for timed purchasing, brand switching, and increased volume are presented, as well as some potential problems like lack of brand building and orienting managers to the short-term.
Pharma/Medical Represnative training
This document discusses the on-call and off-call processes for pharmaceutical sales representatives. It outlines the key steps in the on-call process including preparation, detailing products to doctors, distributing inputs, and analyzing each call. The off-call process involves ensuring product availability, reporting, sales closing management, and providing feedback. It emphasizes working as a team and notes that while other companies may be larger, the sales representatives can still be regional leaders through professionalism.
Pay for- performance: Incentive Rewards
Individual, group, and enterprise-wide incentive plans were discussed. Individual plans include piecework, differential piece rates, and standard hour plans. Group plans include team, gainsharing like Rucker, Scanlon, and Improshare plans. Enterprise plans include profit sharing, stock options, and employee stock ownership plans (ESOPs). The purpose of incentives is to motivate employees and increase productivity, morale, loyalty and company profits. Successful plans have desirable, achievable standards and a clear link between incentives and performance.
2015 Pharmaceutical Sales Rep Experience
A perspective on the big trends that are changing pharmaceutical sales and the new best practices and opportunities those trends inspire.
Pay-for-Performance Plan
This document discusses different types of variable pay plans including individual incentive plans and group incentive plans. It provides details on merit pay, lump-sum bonuses, individual spot awards, and examples of individual incentive plans like piecework systems. It also discusses large group incentive plans including gain-sharing plans and profit-sharing plans as well as advantages and disadvantages of group incentive plans. The document provides examples of various pay for performance plans companies can implement.
Medical representative tips
Be honest and stick to the facts when communicating with doctors about drugs. Provide clear, precise information using visuals to illustrate key points and support arguments with evidence from clinical trials. Do not hide disadvantages and maintain constant communication to build strong, trusting relationships with doctors over time through honest and transparent interactions.
Pay for -performance
The document discusses different types of pay-for-performance plans including shop-floor incentives, sales force incentives, executive pay, and team-based pay. It outlines the importance of designing pay plans that support corporate objectives, are fair and equitable, and comply with laws. Different types of team-based pay plans like profit-sharing, gain-sharing, and employee stock ownership plans are described as ways to incentivize and reward employee performance.
Selling Skills For New Med Reps
The document provides guidance on developing selling skills for pharmaceutical sales representatives. It outlines the selling procedure in 6 steps: 1) prospecting, 2) pre-call planning, 3) the call, 4) response handling, 5) closing, and 6) post-call analysis. Key aspects covered include identifying customer needs, presenting product benefits to satisfy needs, dealing with potential objections, and getting commitments. The overall approach is to gradually develop prescription potential with doctors through repeated calls over the long term.
Inside Sales Compensation & Incentives Best Practices
American Association of Inside Sales Professionals (AA-ISP) Seattle chapter webinar on April 26, 2011
9 sales promotion
Sales promotion consists of short-term incentives to encourage immediate or earlier purchase of products and services. Whereas advertising focuses on reasons to buy, sales promotion emphasizes reasons to buy now. Sales promotion makes up 77% of marketing expenditures on average for consumer packaged goods companies. Popular sales promotion techniques include buy-one-get-one-free offers, loyalty programs, discounts, coupons, competitions, and free samples. Marketers must carefully plan sales promotion programs by determining incentive size, participation criteria, promotion period, and evaluating the program's effectiveness and returns on investment.
25 KPIs Every Manager Needs To Know
Key Performance Indicators (KPIs) should be used to understand performance and drive better decision-making. However, most companies struggle to find the vital few KPIs. Here is a list of the 25 top KPIs is use today.
Pharmaceutical selling skills
This document provides an agenda and overview for a pharmaceutical sales training. It covers key selling concepts and steps including defining the customer's needs, presenting product benefits, handling objections, discussing price, and closing the sale. The 7 basic selling steps are outlined as 1) pre-call planning, 2) opening, 3) questioning, 4) presentation, 5) handling objections, 6) closing, and 7) post-call analysis. Key frameworks like DAPA (define, accept, prove, accept) and techniques like the funnel method and sandwich method for discussing price are also summarized. The overall aim is to develop an effective sales approach to create success for pharmaceutical brands.
Orphan Drugs Summit 2015
Changing times ask for solid relationships.
Times are changing. A renewed interest from big pharma in the rare disease landscape
has awakened due to large-scale patent expirations, competition from generics &
biosimilars, anemic pipelines, escalating clinical trial costs and a global health-care
reform. This means that the traditional blockbuster model has become less viable while
the revenue-generating potential of orphan drugs has shown to be huge with a greater
return on investment than non-orphan drugs. According to EvaluatePharma, the orphan
drugs sales will grow at an annual rate of 11% and constitute 19% of the total share of
prescription drugs by 2020, totalling 176 billion dollars.
The rare disease landscape is very complex due to the large amount of stakeholders
involved. Despite their different interests they have one goal in common: getting an
orphan drug approval that will help save or improve lives. But there are many challenges
on the road to orphan drug designation:
• Complex and changing national and regional regulations
• Clinical trial design and finding & keeping patients
• The lack of a central database designed specifically to list patient registries, which
asks for close stakeholder engagement
• Partnering and establishing financing for future development
• Establishing a foundation for price that is balanced and sustainable
• Achieving an efficient and timely access to market with equal access for patients
around the world
• Achieving timely and correct diagnosis to enable higher quality of life and more time
and information for developers
More information: http://www.orphandrugssummit.com/
What can we do to ensure that patients have the medicines they need?
Thousands of people suffer and die because they don't have access to medicines. The main cause of this problem is that prices of medicines are too high, are abusive.
Different actions that governments can adopt to improve access to medicines
Orphan Medicinal Product Designation in the EU - By Compliance Global Inc.
Orphan designation evaluated by the EMA’s Committee for Orphan Medicinal Products to qualify as an orphan medicine for a rare disease
EuroBioForum2014_speaker_simons
Ruud Simons, a program manager from Nictiz in the Netherlands, gave a presentation on personalized medicine from the perspective of health insurers. He discussed several key points:
1) Achieving the "triple aim" of improving patient experience, population health, and reducing costs through practices like benchmarking expensive drugs and treatments tailored to individuals.
2) The importance of standards, interoperability, and international cooperation to connect initiatives and share best practices.
3) The role of patient registries and empowerment in combining data to support clinical decision making and providing patients access to their own health information.
Teresa alves - selling sickness 2010
The document discusses disease awareness campaigns by pharmaceutical companies in Europe. It notes that while EU law prohibits direct advertising of prescription drugs to the public, companies use unbranded campaigns to indirectly promote their products. Several case studies of campaigns are presented that stretch and violate ethical guidelines by inappropriately fear-mongering about diseases and implying the need for specific brand-name drugs without disclosing risks. The document calls for regulatory agencies to better screen such campaigns and ensure companies are not using social media for disguised drug advertising.
Skills interpreting data, understanding policy responses, communicating to th...
'Skills – interpreting data, understanding policy responses, communicating to the public/patient', presentation by Kweku Rockson and Alex Dodoo during MeTA Ghana, CSO & media orientation workshop, 16 April 2009.
Bio vision 2013 lyon
This document summarizes the BioVision 2013 conference held in Lyon, France. It discusses several topics related to biomedical research and innovation. Key points include the importance of supporting young researchers, the potential of gene research this century, positive indicators for the healthcare sector in France, and over 200 million euros currently spent on translational research. The conference featured discussions on synergizing research efforts, supporting startups, new medical treatments, and catalyzing innovation through cross-disciplinary approaches. Speakers represented industry, government, and academia and addressed issues like climate change, regulating drug development and access, and enabling new biomanufacturing technologies.
World No Tobacco Day 2010
For educational purpose only. No copyright infringement intended. All images belong to their respective owners.
Trends & Developments in Healthcare
A presentation made to clinical pharmacology students highlighting recent developments, challenges and advances made. Gives a brief glimpse into different dynamics of developed and developing world.
Sightseeing Pharmacy practice - The way forward
The document discusses future options for community pharmacy practice and trends influencing those options. It outlines four potential models for future pharmacy practice: a shop model focused on over-the-counter sales; a commercial chain model with limited professional services; a "MacPharmacy" model focused only on fast-moving prescriptions; and a professional practice/clinic model providing complex patient care services in collaboration with other health providers. Each model is described and questions are posed about how each option would impact patients, the profession, and monopoly over pharmacy services. Implementation of new practice models is discussed as requiring change management and addressing barriers through a stepwise project plan.
More Related Content
Viewers also liked
Sales promotion: basic sales promotion techniques
This document provides an overview of basic sales promotion techniques. It defines sales promotion as a planned marketing activity that enhances a product or service's appeal and positively changes consumer behavior in return for an additional benefit. The document outlines various types of sales promotions like temporary price discounts, coupons, bonus packs, sampling, premiums, and sweepstakes. It also discusses the impact of promotions on consumers in economic, emotional and informational ways. Additionally, the benefits of promotions for timed purchasing, brand switching, and increased volume are presented, as well as some potential problems like lack of brand building and orienting managers to the short-term.
Pharma/Medical Represnative training
This document discusses the on-call and off-call processes for pharmaceutical sales representatives. It outlines the key steps in the on-call process including preparation, detailing products to doctors, distributing inputs, and analyzing each call. The off-call process involves ensuring product availability, reporting, sales closing management, and providing feedback. It emphasizes working as a team and notes that while other companies may be larger, the sales representatives can still be regional leaders through professionalism.
Pay for- performance: Incentive Rewards
Individual, group, and enterprise-wide incentive plans were discussed. Individual plans include piecework, differential piece rates, and standard hour plans. Group plans include team, gainsharing like Rucker, Scanlon, and Improshare plans. Enterprise plans include profit sharing, stock options, and employee stock ownership plans (ESOPs). The purpose of incentives is to motivate employees and increase productivity, morale, loyalty and company profits. Successful plans have desirable, achievable standards and a clear link between incentives and performance.
2015 Pharmaceutical Sales Rep Experience
A perspective on the big trends that are changing pharmaceutical sales and the new best practices and opportunities those trends inspire.
Pay-for-Performance Plan
This document discusses different types of variable pay plans including individual incentive plans and group incentive plans. It provides details on merit pay, lump-sum bonuses, individual spot awards, and examples of individual incentive plans like piecework systems. It also discusses large group incentive plans including gain-sharing plans and profit-sharing plans as well as advantages and disadvantages of group incentive plans. The document provides examples of various pay for performance plans companies can implement.
Medical representative tips
Be honest and stick to the facts when communicating with doctors about drugs. Provide clear, precise information using visuals to illustrate key points and support arguments with evidence from clinical trials. Do not hide disadvantages and maintain constant communication to build strong, trusting relationships with doctors over time through honest and transparent interactions.
Pay for -performance
The document discusses different types of pay-for-performance plans including shop-floor incentives, sales force incentives, executive pay, and team-based pay. It outlines the importance of designing pay plans that support corporate objectives, are fair and equitable, and comply with laws. Different types of team-based pay plans like profit-sharing, gain-sharing, and employee stock ownership plans are described as ways to incentivize and reward employee performance.
Selling Skills For New Med Reps
The document provides guidance on developing selling skills for pharmaceutical sales representatives. It outlines the selling procedure in 6 steps: 1) prospecting, 2) pre-call planning, 3) the call, 4) response handling, 5) closing, and 6) post-call analysis. Key aspects covered include identifying customer needs, presenting product benefits to satisfy needs, dealing with potential objections, and getting commitments. The overall approach is to gradually develop prescription potential with doctors through repeated calls over the long term.
Inside Sales Compensation & Incentives Best Practices
American Association of Inside Sales Professionals (AA-ISP) Seattle chapter webinar on April 26, 2011
9 sales promotion
Sales promotion consists of short-term incentives to encourage immediate or earlier purchase of products and services. Whereas advertising focuses on reasons to buy, sales promotion emphasizes reasons to buy now. Sales promotion makes up 77% of marketing expenditures on average for consumer packaged goods companies. Popular sales promotion techniques include buy-one-get-one-free offers, loyalty programs, discounts, coupons, competitions, and free samples. Marketers must carefully plan sales promotion programs by determining incentive size, participation criteria, promotion period, and evaluating the program's effectiveness and returns on investment.
25 KPIs Every Manager Needs To Know
Key Performance Indicators (KPIs) should be used to understand performance and drive better decision-making. However, most companies struggle to find the vital few KPIs. Here is a list of the 25 top KPIs is use today.
Pharmaceutical selling skills
This document provides an agenda and overview for a pharmaceutical sales training. It covers key selling concepts and steps including defining the customer's needs, presenting product benefits, handling objections, discussing price, and closing the sale. The 7 basic selling steps are outlined as 1) pre-call planning, 2) opening, 3) questioning, 4) presentation, 5) handling objections, 6) closing, and 7) post-call analysis. Key frameworks like DAPA (define, accept, prove, accept) and techniques like the funnel method and sandwich method for discussing price are also summarized. The overall aim is to develop an effective sales approach to create success for pharmaceutical brands.
Viewers also liked (12)
Inside Sales Compensation & Incentives Best Practices
Inside Sales Compensation & Incentives Best Practices
Similar to Michel Dutree - Selling Sickness 2010
Orphan Drugs Summit 2015
Changing times ask for solid relationships.
Times are changing. A renewed interest from big pharma in the rare disease landscape
has awakened due to large-scale patent expirations, competition from generics &
biosimilars, anemic pipelines, escalating clinical trial costs and a global health-care
reform. This means that the traditional blockbuster model has become less viable while
the revenue-generating potential of orphan drugs has shown to be huge with a greater
return on investment than non-orphan drugs. According to EvaluatePharma, the orphan
drugs sales will grow at an annual rate of 11% and constitute 19% of the total share of
prescription drugs by 2020, totalling 176 billion dollars.
The rare disease landscape is very complex due to the large amount of stakeholders
involved. Despite their different interests they have one goal in common: getting an
orphan drug approval that will help save or improve lives. But there are many challenges
on the road to orphan drug designation:
• Complex and changing national and regional regulations
• Clinical trial design and finding & keeping patients
• The lack of a central database designed specifically to list patient registries, which
asks for close stakeholder engagement
• Partnering and establishing financing for future development
• Establishing a foundation for price that is balanced and sustainable
• Achieving an efficient and timely access to market with equal access for patients
around the world
• Achieving timely and correct diagnosis to enable higher quality of life and more time
and information for developers
More information: http://www.orphandrugssummit.com/
What can we do to ensure that patients have the medicines they need?
Thousands of people suffer and die because they don't have access to medicines. The main cause of this problem is that prices of medicines are too high, are abusive.
Different actions that governments can adopt to improve access to medicines
Orphan Medicinal Product Designation in the EU - By Compliance Global Inc.
Orphan designation evaluated by the EMA’s Committee for Orphan Medicinal Products to qualify as an orphan medicine for a rare disease
EuroBioForum2014_speaker_simons
Ruud Simons, a program manager from Nictiz in the Netherlands, gave a presentation on personalized medicine from the perspective of health insurers. He discussed several key points:
1) Achieving the "triple aim" of improving patient experience, population health, and reducing costs through practices like benchmarking expensive drugs and treatments tailored to individuals.
2) The importance of standards, interoperability, and international cooperation to connect initiatives and share best practices.
3) The role of patient registries and empowerment in combining data to support clinical decision making and providing patients access to their own health information.
Teresa alves - selling sickness 2010
The document discusses disease awareness campaigns by pharmaceutical companies in Europe. It notes that while EU law prohibits direct advertising of prescription drugs to the public, companies use unbranded campaigns to indirectly promote their products. Several case studies of campaigns are presented that stretch and violate ethical guidelines by inappropriately fear-mongering about diseases and implying the need for specific brand-name drugs without disclosing risks. The document calls for regulatory agencies to better screen such campaigns and ensure companies are not using social media for disguised drug advertising.
Skills interpreting data, understanding policy responses, communicating to th...
'Skills – interpreting data, understanding policy responses, communicating to the public/patient', presentation by Kweku Rockson and Alex Dodoo during MeTA Ghana, CSO & media orientation workshop, 16 April 2009.
Bio vision 2013 lyon
This document summarizes the BioVision 2013 conference held in Lyon, France. It discusses several topics related to biomedical research and innovation. Key points include the importance of supporting young researchers, the potential of gene research this century, positive indicators for the healthcare sector in France, and over 200 million euros currently spent on translational research. The conference featured discussions on synergizing research efforts, supporting startups, new medical treatments, and catalyzing innovation through cross-disciplinary approaches. Speakers represented industry, government, and academia and addressed issues like climate change, regulating drug development and access, and enabling new biomanufacturing technologies.
World No Tobacco Day 2010
For educational purpose only. No copyright infringement intended. All images belong to their respective owners.
Trends & Developments in Healthcare
A presentation made to clinical pharmacology students highlighting recent developments, challenges and advances made. Gives a brief glimpse into different dynamics of developed and developing world.
Sightseeing Pharmacy practice - The way forward
The document discusses future options for community pharmacy practice and trends influencing those options. It outlines four potential models for future pharmacy practice: a shop model focused on over-the-counter sales; a commercial chain model with limited professional services; a "MacPharmacy" model focused only on fast-moving prescriptions; and a professional practice/clinic model providing complex patient care services in collaboration with other health providers. Each model is described and questions are posed about how each option would impact patients, the profession, and monopoly over pharmacy services. Implementation of new practice models is discussed as requiring change management and addressing barriers through a stepwise project plan.
Pharmaceuticals and HIV/AIDS
This presentation quickly presents the current dilemma with generic drugs for HIV/AIDS and 4 proposed solutions to the "patent problem."
Health Exchange: Access to medicines April 2010
The document discusses improving access to essential medicines and identifies several problems. It notes that two billion people lack access to essential medicines, and there is a large price variation for treatments between countries. Stockouts of essential medicines also occur when health facilities experience shortages. The document proposes several solutions, including greater use of generics, changing how innovation is rewarded, improving governance and transparency, and partnerships between different stakeholders.
Anti- Counterfeiting Pharma 2015
This document provides an agenda and details for the "Anti-Counterfeiting Pharma 2015" conference taking place on March 11-12, 2015 in London. The conference will feature presentations and panel discussions on topics related to anti-counterfeiting strategies in the pharmaceutical industry, including serialisation, supply chain security, legislation, mobile technologies, and tackling online pharmaceutical crime. Prominent speakers will represent organizations such as Sanofi, Shire Pharmaceuticals, MHRA, GS1, and Arnold & Porter LLP. Attendees will include professionals from R&D, supply chain, packaging, and other relevant roles within the pharmaceutical industry.
Quality of life experiences No.2
Meet the experts and find out how technology is changing the future of healthcare, quality of life trends and figures, how to help patients adapt to a change in rhythm, how to train a staff that CARES, holistic approaches to patient care, mealtime management and news around the world.
Did you know newsletter n2-2015
The board of Europa Uomo met during the 30th annual meeting of the European Association of Urology in Madrid, Spain from March 20-24, 2015. The summary includes:
1) The board discussed initiatives of the Board and upcoming adoption of a Strategic Plan at their annual general meeting in Warsaw.
2) The article discusses common shortcomings in prostate cancer care across Europe, including limited availability of prostate cancer screening in only four European countries.
3) It provides an overview of contents of the newsletter, including articles on depression and anxiety in prostate cancer patients, clinical trials registration and reporting in Europe, and cancer support services in Ireland.
R bleddyn v rees international opportunities for healthcare services, researc...
The speaker discusses international opportunities in healthcare services, research, and innovation. He is the non-executive director of the European Connected Health Alliance and advises health departments in several countries. He outlines drivers for international opportunities such as disruptive technologies, aging populations, and the needs of developing countries. Examples of opportunities discussed include partnerships to run hospitals in the Middle East, research funding programs, and digital health services.
Overheard at TEDMED 2015: Let's Dance
Is healthwashing the new greenwashing? Are we placing too much faith in technology? These are just some of the questions that emerged from our conversation around making health a shared value at TEDMED 2015. Check out our blog, "Overheard at TEDMED: Let's Dance," for more details: http://blog.tedmed.com/overheard-at-tedmed/
Dr Amir Khoury Qrce Nov 8 As Sent
The document discusses issues around balancing intellectual property rights and access to patented medicines in developing countries. It proposes a model that would allow for compulsory licensing of medicines while still preserving incentives for pharmaceutical innovation. Key aspects include allowing developing countries to declare "medical emergencies" to access affordable generic medicines without delay, establishing impartial bodies like WHO to assess such determinations, and ensuring compulsory licenses are limited in scope and term to prevent abuse. The goal is to reform intellectual property rules in a balanced way that addresses public health needs in the global south.
Conferências saúdecuf david doherty
The document discusses the rise of mobile technology and its impact on healthcare. It notes that the author's first memory in life was the sound of telecoms in healthcare. Mobile phones are now ubiquitous, with over 6 billion subscriptions globally. The convergence of mobile and healthcare is redesigning the industry, enabling remote access to documented video consultations with doctors through services like 3G Doctor. Undocumented care fails to engage patients, while mobile health solutions allow greater access to documented care through telemedicine.
Conferências saúdecuf david doherty
The document discusses the history and opportunities of mobile health (mHealth). It notes that the author's first memory was of telecoms in healthcare. mHealth leverages mobile technology for health purposes, with over 6 billion mobile subscriptions globally. The convergence of mobile and healthcare is now redesigning the industry for the digital age. Services like 3G Doctor provide documented video consultations with registered doctors over mobile.
Similar to Michel Dutree - Selling Sickness 2010 (20)
What can we do to ensure that patients have the medicines they need?
What can we do to ensure that patients have the medicines they need?
Orphan Medicinal Product Designation in the EU - By Compliance Global Inc.
Orphan Medicinal Product Designation in the EU - By Compliance Global Inc.
Skills interpreting data, understanding policy responses, communicating to th...
Skills interpreting data, understanding policy responses, communicating to th...
R bleddyn v rees international opportunities for healthcare services, researc...
R bleddyn v rees international opportunities for healthcare services, researc...
More from Gezonde scepsis
Trudy Dehue - Selling Sickness 2010
This document discusses how clinical trials have increasingly become marketing instruments for pharmaceutical companies rather than objective scientific research. It argues that when researchers are driven to serve companies' needs, trials become demonstrations, research becomes marketing, articles become advertisements, and authors become authorities for the company. It suggests that clinical research organizations should be driven to serve civilians' needs rather than pharmaceutical companies' needs by having financially independent agencies act as an interface between researchers and companies.
Peter Mansfield - Selling Sickness 2010
International cooperation is difficult but necessary to address global health issues. It requires overcoming barriers between nations like language and wealth differences, and between individuals with differing worldviews. Cooperation is achievable through open dialogue to reconcile different interests and find equitable, win-win solutions. Global forums could further cooperation by debating and designing reforms to reduce misleading health information.
Lode Wigersma - Selling Sickness 2010
The document summarizes guidelines for providing information about diseases and prescription medicines to the public in the Netherlands. It outlines the Dutch regulatory system for pharmaceutical advertising and promotion. The guidelines were developed in response to increased disease awareness campaigns and public demand for prescription medicine information. They establish standards for balanced, complete information about diseases and technical information about prescription medicines. The guidelines apply to all parties providing such information and include conditions like not misleading the public or leading to unnecessary medical treatment. A transitional period was provided for adjusting existing information to the new guidelines.
Bert Leufkens - Selling Sickness 2010
This document summarizes a presentation given by Bert Leufkens, Chair of the Dutch Medicines Evaluation Board, on the topic of "Selling sickness". Some key points from the document include:
- Regulators play an important role in regulating marketing approval of new drugs to ensure they provide benefit to patients and public health while balancing industry interests.
- There are concerns about "incomplete innovation" where not all medical needs are addressed, as well as "orphanisation" where the antibiotic drug pipeline is emptying.
- Regulators aim to serve as "Knights" protecting public health rather than "Knaves" focused only on procedures and self-interest.
- Throughout the drug lifecycle, regulators consider questions
Kees de joncheere - Selling Sickness 2010
Promotional practices by pharmaceutical companies can negatively impact public health, prescribing behaviors, and trust in the industry and medical profession. Aggressive marketing has led to unsafe drugs remaining on the market longer and increased prescribing of new drugs over older generics. While codes aim to ensure promotion provides reliable and balanced information, evidence shows marketing frequently downplays risks, lacks scientific support, and inappropriately influences prescribing through gifts, trips and interactions with sales representatives. Stricter regulation and adherence to ethical standards are needed to prioritize patient well-being over commercial interests.
Henk Eleveld - Selling Sickness 2010
The document discusses Menzis, a large Dutch health insurer, and its preference policy for prescribing generic medicines. The policy aims to use the lowest priced generic equivalent once a brand name drug's patent expires. Pharmacists previously earned high margins substituting generics, without passing savings to customers. Under the preference policy, manufacturers submit annual prices and the lowest bidder wins preferred status for reimbursement. This has saved over 500 million euros annually. The policy could expand to include more drugs and be adopted in other countries to promote transparency and realistic drug prices.
Graham Dukes - Selling Sickness 2010
This document outlines 6 points of concern regarding commercial advertising practices: 1) questionable commercial detailing traditions, 2) inadequacy of retrospective control over advertising, 3) lack of flexibility in advertising practices, 4) failure to control rising advertising costs, 5) inadequate legal support from courts, and 6) insufficient understanding of advertising issues among politicians.
Meindert Boysen Selling Sickness 2010
NICE is the independent organization responsible for providing national guidance on health promotion and prevention and treatment of illness in the UK. It produces guidance in public health, health technologies, and clinical practice based on the best available evidence. NICE uses health economic analysis to determine the cost-effectiveness of new drugs and treatments for the NHS. The majority of its recommendations are positive, with around 70% approving new cancer treatments. NICE works to ensure its guidance is implemented locally through field team support to those adopting the guidance.
Hilda Bastian - Selling Sickness 2010
- The German Institute for Quality and Efficiency in Health Care (IQWiG) was established in 2004 to provide evidence-based and unbiased patient information to empower citizens.
- IQWiG develops patient information using systematic methods to minimize bias and address uncertainties. Information is kept up-to-date and non-directive.
- Producing high-quality, translated patient information that preserves accuracy is challenging but important. IQWiG aims to expand its evidence-based patient encyclopedia to over 1,000 articles on various health topics.
Ray Moynihan- Selling Sickness Amsterdam
1. The document discusses how drug companies have helped construct the medical condition of Female Sexual Dysfunction (FSD) by influencing its definition, inflating prevalence estimates, and developing diagnosis tools and education programs.
2. Studies finding higher prevalence of FSD have largely been funded by drug companies, while non-industry studies find lower rates.
3. Drugs to treat FSD conditions like Hypoactive Sexual Desire Disorder (HSDD) have not proven effective and may carry health risks, yet drug companies continue direct-to-consumer campaigns to promote "diseases" and treatments.
Josée hansen igz
The document discusses supervision and law enforcement of pharmaceutical marketing in the Netherlands. It describes the country's regulatory framework, the roles of different regulators like the Health Care Inspectorate and codes of conduct organizations. It also outlines enforcement options for minor, intermediate, and serious violations ranging from self-regulatory measures to fines. Complications around areas like disease mongering and conflicts of interest in clinical guidelines are also mentioned.
Ilaria passarani - Selling Sickness 2010
1. The document discusses the influence of pharmaceutical companies on patients through disease awareness campaigns and direct-to-consumer information. It argues that such information is often promotional rather than objective.
2. Recommendations are made to ensure information provided to the public is unbiased and meets consumer rights to high-quality, non-promotional health information. More independent research is also needed to study the impact and costs of disease awareness campaigns.
3. The European Commission's proposal on information to patients aims to distinguish information from promotion but could still allow promotion; it needs stricter rules to avoid unethical practices.
Brian Ager - Selling Sickness 2010
The document discusses the importance of the pharmaceutical industry to Europe. It summarizes that the industry directly employs over 630,000 people in Europe and contributes 3.5% of EU manufacturing value. It is one of the few remaining high-technology industries in Europe. The industry also plays a dual role as a major economic contributor and in improving health outcomes for European citizens. However, access to new medicines remains a challenge due to the high costs of research and regulatory hurdles.
Dee Mangin Selling Sickness 2010
This document discusses the aggressive marketing tactics used by pharmaceutical companies to promote the use of antidepressants, especially SSRIs like Paxil. It describes how companies expanded disease definitions, ignored safety issues, and promoted the drugs to vulnerable groups like pregnant women to significantly increase profits. The document argues that regulation and information systems have failed and that promotion has become disconnected from science. It calls for learning from these issues to better regulate drug licensing, promotion, and ensure independent information for physicians and consumers.
More from Gezonde scepsis (15)
Allen frances dsm5 - Selling Sickness Conference 2010
Allen frances dsm5 - Selling Sickness Conference 2010
Recently uploaded
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
It includes regulation of combination products and medical devices. FDA and industry liaisons.
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
- Video recording of this lecture in English language: https://youtu.be/kqbnxVAZs-0
- Video recording of this lecture in Arabic language: https://youtu.be/SINlygW1Mpc
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Role of Mukta Pishti in the Management of Hyperthyroidism
Muktapishti is a traditional Ayurvedic preparation made from Shoditha Mukta (Purified Pearl), is believed to help regulate thyroid function and reduce symptoms of hyperthyroidism due to its cooling and balancing properties. Clinical evidence on its efficacy remains limited, necessitating further research to validate its therapeutic benefits.
Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS). Parc Taulí. Sabadell
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptxHolistified Wellness
We’re talking about Vedic Meditation, a form of meditation that has been around for at least 5,000 years. Back then, the people who lived in the Indus Valley, now known as India and Pakistan, practised meditation as a fundamental part of daily life. This knowledge that has given us yoga and Ayurveda, was known as Veda, hence the name Vedic. And though there are some written records, the practice has been passed down verbally from generation to generation.Ketone bodies and metabolism-biochemistry
This slide consists of all the topics of ketone . This can be used for exam purpose for writing about Diabetic keto acidosis etc . Thank you
Top Effective Soaps for Fungal Skin Infections in India
Swisschem Dermacare has mentioned the List of The Best Antifungal Soap In India 2022. All of these soaps are trusted by various Dermatology Experts.
Efficacy of Avartana Sneha in Ayurveda
Avartana Sneha is a unique method of Preparation of Sneha Kalpana in Ayurveda, mainly it is indicated for the Vataja rogas.
The Best Ayurvedic Antacid Tablets in India
Treat the symptoms of indigestion, heartburn and stomach reflux with the 10 Best Ayurvedic Antacid Tablets in India.
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by Stamler, Verified Chapters 1 - 33, Complete Newest Version Community Health Nursing A Canadian Perspective, 5th Edition by Stamler, Verified Chapters 1 - 33, Complete Newest Version Community Health Nursing A Canadian Perspective, 5th Edition by Stamler Community Health Nursing A Canadian Perspective, 5th Edition TEST BANK by Stamler Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Pdf Chapters Download Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Pdf Download Stuvia Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Study Guide Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Ebook Download Stuvia Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Questions and Answers Quizlet Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Studocu Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Quizlet Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Pdf Chapters Download Community Health Nursing A Canadian Perspective, 5th Edition Pdf Download Course Hero Community Health Nursing A Canadian Perspective, 5th Edition Answers Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Ebook Download Course hero Community Health Nursing A Canadian Perspective, 5th Edition Questions and Answers Community Health Nursing A Canadian Perspective, 5th Edition Studocu Community Health Nursing A Canadian Perspective, 5th Edition Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Pdf Chapters Download Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Pdf Download Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Study Guide Questions and Answers Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Ebook Download Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Questions Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Studocu Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Stuvia
share - Lions, tigers, AI and health misinformation, oh my!.pptx
• Pitfalls and pivots needed to use AI effectively in public health
• Evidence-based strategies to address health misinformation effectively
• Building trust with communities online and offline
• Equipping health professionals to address questions, concerns and health misinformation
• Assessing risk and mitigating harm from adverse health narratives in communities, health workforce and health system
Journal Article Review on Rasamanikya
Rasamanikya is a excellent preparation in the field of Rasashastra, it is used in various Kushtha Roga, Shwasa, Vicharchika, Bhagandara, Vatarakta, and Phiranga Roga. In this article Preparation& Comparative analytical profile for both Formulationon i.e Rasamanikya prepared by Kushmanda swarasa & Churnodhaka Shodita Haratala. The study aims to provide insights into the comparative efficacy and analytical aspects of these formulations for enhanced therapeutic outcomes.
Recently uploaded (20)
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Role of Mukta Pishti in the Management of Hyperthyroidism
Role of Mukta Pishti in the Management of Hyperthyroidism
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
Top Effective Soaps for Fungal Skin Infections in India
Top Effective Soaps for Fungal Skin Infections in India
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...
share - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptx
Michel Dutree - Selling Sickness 2010
- 1. Selling Health! Michel A. Dutrée MD PhDgeneral manager Nefarma8 oktober 2010
- 3. Expert to the Dutch Safety Council
- 4. Board member CGR
- 5. Member Executive Comittee EFPIA
- 6. Council member IFPMA
- 7. Board member VNO-NCW
- 9. Care for hungry people vs laying off people
- 10. Reducing carbon footprint vs fighting flight tax
- 11. Developing electrical car VOLTAvsfighting zero emission cars
- 12. Pharma companies Protecting IP-rights even in developing countriesvsContributing to developing countries
- 13. Good guys and bad guys? An immoral division!
- 14. Dialogue is the way
- 15. Mrs Jones and diapers Plaatje mrs Jones
- 16. Mrs Jones and drugs
- 17. Society is our judge
- 18. Benefits from medicines Wheel chair vs walking again
- 19. Benefits from medicines Pills vs surgery
- 20. Who are the decision makers? Pharma and the watch dogs
- 21. Pharmaceutical sector We are selling health!
- 22. Selling Sickness Do not decide FOR society but WITH society!
- 24. reimbursement
- 25. added value
- 30. Many greetings!
- 31. Statement for discussion To oppose is to continue, to cooperate is to change.